RegulatoryGuideline · final

MHRA adds antidepressant safety communications to its Safety Public Assessment Reports page

🇬🇧 MHRA · Thu 15 Oct 2026

The UK regulator's update on 15 October 2026 links an 'Antidepressants – updated safety communications' report within its collection of national medicines safety assessments.

The Medicines and Healthcare products Regulatory Agency (MHRA) updated its Safety Public Assessment Reports page on 15 October 2026. The change adds a link to a report titled 'Antidepressants – updated safety communications', which now appears under the 2026 heading.

The page collects reports explaining the agency's assessment of the scientific evidence behind regulatory decisions on the safety of medicines or medicine classes. The MHRA says these cover issues assessed nationally by the Commission on Human Medicines (CHM) or its advisory groups, and that it prioritises publishing reports tied to major national regulatory action.

Other 2026 entries are a report on the risk of dementia with bladder anticholinergics, added on 27 July 2026, and reports on improving information supplied with gabapentinoids, benzodiazepines and Z-drugs, and on the impact of isotretinoin prescribing recommendations, both added on 26 January 2026. The source does not set out the content or conclusions of the antidepressant report.

The MHRA stresses that the reports show the evidence available when a regulatory decision was made, a 'snapshot' of the clinical landscape at that time. They are not intended to provide clinical advice. It also notes that since 2012 most safety issues have been assessed at EU level, with those reports found on the websites of the European Medicines Agency or the Heads of Medicines Agencies.

What it means for your team

  • Regulatory and PV teams tracking UK safety actions should review the new antidepressant entry, as the page update gives no detail of its findings.
  • Because the reports are a snapshot of evidence at the time of a decision, teams should check them alongside current product information and the monthly Drug Safety Update.
  • The 2026 list also includes bladder anticholinergics and dementia, gabapentinoids, benzodiazepines and Z-drugs, and isotretinoin, which are relevant to UK risk-minimisation monitoring.

Official guideline text: MHRA ↗

Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.

More Regulatory All →